{
  "context": {
    "rules": [
      "Rule1: If batch Z fails quality testing, then either excipient Y experiences raw material shortage or excipient Y experiences supplier delay.",
      "Rule2: Either batch Z fails quality testing or contamination is detected in batch Z.",
      "Rule3: Provided that contamination is detected in batch Z, it follows that either excipient Y has raw material shortage or excipient Y has supplier delay.",
      "Rule4: Whenever formulation W undergoes accelerated aging testing, either formulation W passes stability study or compound X becomes profitable.",
      "Rule5: Formulation W undergoes accelerated aging testing or formulation W undergoes real-time stability testing.",
      "Rule6: If batch Z is rejected, then batch Z is subject to product recall.",
      "Rule7: Provided that plant A undergoes quality control inspection, if it is not the case that whenever formulation W undergoes real-time stability testing then either formulation W passes stability study or compound X is profitable, then batch Z is rejected.",
      "Rule8: Either plant A undergoes quality control inspection or plant A has audit findings.",
      "Rule9: Whenever plant A has audit findings, if it is not the case that under the condition that formulation W undergoes real-time stability testing then either formulation W passes stability study or compound X is profitable, then batch Z is rejected.",
      "Rule10: Provided that compound X has patent filing, it follows that compound X has intellectual property protection.",
      "Rule11: Under the condition that compound X undergoes prior art search, if compound X has intellectual property protection then compound X has patent protection.",
      "Rule12: If manufacturing line B undergoes process validation, then provided that compound X does not undergo prior art search, compound X receives patent rejection.",
      "Rule13: Whenever manufacturing line B has equipment qualification, if compound X does not undergo prior art search then compound X receives patent rejection.",
      "Rule14: If manufacturing line B has validation protocol, then manufacturing line B undergoes process validation.",
      "Rule15: Either manufacturing line B has validation protocol or manufacturing line B has qualification study.",
      "Rule16: Provided that manufacturing line B has qualification study, it follows that manufacturing line B has equipment qualification.",
      "Rule17: If pill form undergoes dissolution testing, then formulation W passes stability study.",
      "Rule18: Under the condition that pill form undergoes bioavailability study, compound X becomes profitable.",
      "Rule19: Provided that compound X has excipient modifications, compound X has delivery system updates.",
      "Rule20: If compound X receives market authorization, then compound X obtains regulatory approval.",
      "Rule21: Whenever manufacturing line B has equipment upgrades, manufacturing line B has process improvements.",
      "Rule22: Provided that manufacturing line B has CAPA implementation, if it is not the case that either manufacturing line B undergoes process validation or manufacturing line B has equipment qualification, then manufacturing line B has equipment upgrades.",
      "Rule23: Either manufacturing line B has CAPA implementation or manufacturing line B has deviation management.",
      "Rule24: Under the condition that manufacturing line B has deviation management, if it is not the case that either manufacturing line B undergoes process validation or manufacturing line B has equipment qualification, then manufacturing line B has equipment upgrades.",
      "Rule25: Either compound X undergoes production scale-up or compound X undergoes manufacturing optimization.",
      "Rule26: Whenever compound X undergoes manufacturing optimization, compound X becomes profitable.",
      "Rule27: Either compound X experiences supply chain issues or if compound X undergoes production scale-up then compound X is profitable.",
      "Rule28: If excipient Y has raw material shortage, then compound X does not experience supply chain issues.",
      "Rule29: Provided that excipient Y has supplier delay, compound X does not experience supply chain issues.",
      "Rule30: Provided that it is not the case that under the condition that formulation W undergoes real-time stability testing then either formulation W passes stability study or compound X is profitable, batch Z is not subject to product recall.",
      "Rule31: Whenever it is not the case that either manufacturing line B undergoes process validation or manufacturing line B has equipment qualification, manufacturing line B does not have process improvements.",
      "Rule32: If it is not the case that whenever compound X completes Phase III trials then compound X obtains regulatory approval, then compound X has efficacy data.",
      "Rule33: Provided that it is not the case that either compound X has safety profile data or compound X does not have efficacy data, compound X has adverse events.",
      "Rule34: Whenever it is not the case that either pill form undergoes dissolution testing or pill form undergoes bioavailability study, compound X has excipient modifications.",
      "Rule35: If it is not the case that either pill form undergoes dissolution testing or pill form undergoes bioavailability study, then compound X does not have formulation changes.",
      "Rule36: Provided that it is not the case that either compound X has shelf life extension or if compound X has delivery system updates then compound X has formulation changes, compound X has packaging redesign.",
      "Rule37: Under the condition that it is not the case that either compound X has shelf life extension or if compound X has delivery system updates then compound X has formulation changes, compound X does not have packaging redesign.",
      "Rule38: If it is not the case that whenever it is not the case that if compound X is not profitable then compound X is not approved for research then compound X has clinical trial success, then compound X completes Phase III trials.",
      "Rule39: Whenever it is not the case that if it is not the case that if compound X is not profitable then compound X is not approved for research then compound X has clinical trial success, compound X receives market authorization.",
      "Rule40: Under the condition that it is not the case that provided that it is not the case that if compound X is not profitable then compound X is not approved for research then compound X has clinical trial success, compound X does not obtain regulatory approval.",
      "Rule41: Provided that it is not the case that if compound X is not profitable then compound X is not approved for research, compound X does not have clinical trial success.",
      "Rule42: Under the condition that compound X does not undergo prior art search, compound X does not receive patent rejection.",
      "Rule43: If compound X is not profitable, then compound X is approved for research.",
      "Rule44: Whenever compound X is not profitable, compound X has patent filing."
    ],
    "facts": [
      "Fact1: Formulation W does not pass stability study.",
      "Fact2: Compound X does not have patent protection.",
      "Fact3: Compound X does not have safety profile data.",
      "Fact4: Compound X does not have adverse events.",
      "Fact5: Compound X does not have shelf life extension."
    ]
  },
  "question": "Compound X is a profitable product."
}